Siegel RL, Miller KD, Wagle NS, Cancer statistics JA. 2023. CA: A Cancer Journal for Clinicians 2023;73(1):17–48.

Shafi AA, Yen AE, Weigel NL. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol Ther. 2013;140(3):223–38.

Article  CAS  PubMed  Google Scholar 

Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate. 2004;61(4):332–53.

Article  CAS  PubMed  Google Scholar 

Attard G, Parker C, Eeles RA, Schröder F, Tomlins SA, Tannock I, et al. Prostate cancer. Lancet. 2016;387(10013):70–82.

Article  PubMed  Google Scholar 

Dutt SS, Gao AC. Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol. 2009;5(9):1403–13.

Article  CAS  PubMed  Google Scholar 

Sharifi N. Mechanisms of androgen receptor activation in castration-resistant prostate Cancer. Endocrinology. 2013;154(11):4010–17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Galletti G, Leach BI, Lam L, Tagawa ST. Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer. Cancer Treat Rev. 2017;57:16–27.

Article  CAS  PubMed  Google Scholar 

Sprenger CCT, Plymate SR. The link between androgen receptor splice variants and castration-resistant prostate Cancer. Horm Cancer. 2014;5(4):207–17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and Resistance to Enzalutamide and Abiraterone in prostate Cancer. N Engl J Med. 2014;371(11):1028–38.

Article  PubMed  PubMed Central  Google Scholar 

Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M et al. Androgen receptor splice variant 7 and efficacy of Taxane Chemotherapy in patients with metastatic castration-resistant prostate Cancer. JAMA Oncol 2015;1(5).

Sun S, Sprenger CCT, Vessella RL, Haugk K, Soriano K, Mostaghel EA, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest. 2010;120(8):2715–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB. Understanding the mechanisms of Androgen Deprivation resistance in prostate Cancer at the Molecular Level. Eur Urol. 2015;67(3):470–79.

Article  CAS  PubMed  Google Scholar 

Moon SJ, Jeong BC, Kim HJ, Lim JE, Kwon GY, Kim JH. DBC1 promotes castration-resistant prostate cancer by positively regulating DNA binding and stability of AR-V7. Oncogene. 2017;37(10):1326–39.

Article  PubMed  Google Scholar 

Zhang B, Zhang M, Shen C, Liu G, Zhang F, Hou J et al. LncRNA PCBP1-AS1-mediated AR/AR-V7 deubiquitination enhances prostate cancer enzalutamide resistance. Cell Death Dis 2021;12(10).

Gao L, Zhang W, Zhang J, Liu J, Sun F, Liu H, et al. KIF15-Mediated stabilization of AR and AR-V7 contributes to Enzalutamide Resistance in prostate Cancer. Cancer Res. 2021;81(4):1026–39.

Article  CAS  PubMed  Google Scholar 

Touré A, Dorseuil O, Morin L, Timmons P, Jégou B, Reibel L, et al. MgcRacGAP, a New Human GTPase-activating protein for Rac and Cdc42 similar to Drosophila rotundRacGAP Gene product, is expressed in male germ cells. J Biol Chem. 1998;273(11):6019–23.

Article  PubMed  Google Scholar 

Hirose K, Kawashima T, Iwamoto I, Nosaka T, Kitamura T. MgcRacGAP is involved in Cytokinesis through associating with mitotic spindle and Midbody. J Biol Chem. 2001;276(8):5821–28.

Article  CAS  PubMed  Google Scholar 

Nishimura Y, Yonemura S. Centralspindlin regulates ECT2 and RhoA accumulation at the equatorial cortex during cytokinesis. J Cell Sci. 2006;119(1):104–14.

Article  CAS  PubMed  Google Scholar 

Kamijo K, Ohara N, Abe M, Uchimura T, Hosoya H, Lee J-S, et al. Dissecting the role of rho-mediated signaling in Contractile Ring formation. Mol Biol Cell. 2006;17(1):43–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao WM. Fang G MgcRacGAP controls the assembly of the contractile ring and the initiation of cytokinesis. Proc Natl Acad Sci U S A. 2005;102(37):13158–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yamazaki D, Kurisu S, Takenawa T. Involvement of Rac and rho signaling in cancer cell motility in 3D substrates. Oncogene. 2009;28(13):1570–83.

Article  CAS  PubMed  Google Scholar 

Sanz-Moreno V, Gadea G, Ahn J, Paterson H, Marra P, Pinner S, et al. Rac Activation and Inactivation Control Plasticity of Tumor Cell Movement. Cell. 2008;135(3):510–23.

Article  CAS  PubMed  Google Scholar 

Sahai E. Mechanisms of cancer cell invasion. Curr Opin Genet Dev. 2005;15(1):87–96.

Article  CAS  PubMed  Google Scholar 

Law RA, Kiepas A, Desta HE, Perez Ipina E, Parlani M, Lee SJ, et al. Cytokinesis machinery promotes cell dissociation from collectively migrating strands in confinement. Sci Adv. 2023;9(2):eabq6480.

Article  PubMed  PubMed Central  Google Scholar 

Zhang T, Wang C, Wang K, Liang Y, Liu T, Feng L et al. RacGAP1 promotes the malignant progression of cervical cancer by regulating AP-1 via miR-192 and p-JNK. Cell Death Dis 2022;13(7).

Yang X-M, Cao X-Y, He P, Li J, Feng M-X, Zhang Y-L, et al. Overexpression of rac GTPase activating protein 1 contributes to proliferation of Cancer cells by reducing Hippo Signaling to Promote Cytokinesis. Gastroenterology. 2018;155(4):1233–e4922.

Article  CAS  PubMed  Google Scholar 

Imaoka H, Toiyama Y, Saigusa S, Kawamura M, Kawamoto A, Okugawa Y, et al. RacGAP1 expression, increasing tumor malignant potential, as a predictive biomarker for lymph node metastasis and poor prognosis in colorectal cancer. Carcinogenesis. 2015;36(3):346–54.

Article  CAS  PubMed  Google Scholar 

Bian R, Dang W, Song X, Liu L, Jiang C, Yang Y, et al. Rac GTPase activating protein 1 promotes gallbladder cancer via binding DNA ligase 3 to reduce apoptosis. Int J Biol Sci. 2021;17(9):2167–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Song Z, Cao Q, Guo B, Zhao Y, Li X, Lou N, et al. Overexpression of RACGAP1 by E2F1 promotes neuroendocrine differentiation of prostate Cancer by stabilizing EZH2 expression. Aging Disease. 2023;14(5):1757–74.

Article  PubMed  PubMed Central  Google Scholar 

Liu J, Zhang R, Su T, Zhou Q, Gao L, He Z et al. Targeting PHB1 to inhibit castration-resistant prostate cancer progression in vitro and in vivo. J Experimental Clin Cancer Res 2023;42(1).

Cato L, de Tribolet-Hardy J, Lee I, Rottenberg JT, Coleman I, Melchers D et al. ARv7 represses tumor-suppressor genes in castration-resistant prostate Cancer. Cancer Cell 2019;35(3).

Malik R, Khan AP, Asangani IA, Cieślik M, Prensner JR, Wang X, et al. Targeting the MLL complex in castration-resistant prostate cancer. Nat Med. 2015;21(4):344–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Skovronsky DM, Pijak DS, Doms RW, Lee VM. A distinct ER/IC gamma-secretase competes with the proteasome for cleavage of APP. Biochemistry. 2000;39(4):810–7.

Article  CAS  PubMed  Google Scholar 

Ohkuma S, Poole B. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc Natl Acad Sci U S A. 1978;75(7):3327–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Y, Xie N, Gleave ME, Rennie PS, Dong. X AR-v7 protein expression is regulated by protein kinase and phosphatase. Oncotarget. 2015;6(32):33743–54.

Article